Anti-cancer biotech company Aktis Oncology (AKTS.US) has an IPO price of $16-18 per share and plans to raise US$212 million

The Zhitong Finance App learned that the clinical-stage biotech company Aktis Oncology Inc. (AKTS.US), which focuses on radiopharmaceutical therapy research and development, plans to conduct an initial public offering (IPO) in the US, raising up to US$212 million.

According to the company's prospectus submitted to the US Securities and Exchange Commission on Monday, it plans to issue 11.8 million shares at a price of 16-18 US dollars each. Based on the upper limit of the issue price range, combined with the number of tradable shares disclosed in the prospectus, the valuation of this Boston-based company would reach approximately US$840 million.

The proposed listing comes at a time when early 2026 is likely to usher in a wave of intensive IPOs. Diabetes management company MiniMed Group (MMED.US) is planning to go public after spin-off from medical giant Medtronic (MDT.US), while construction equipment leasing companies EquipmentShare.com Inc. (EQPT.US) and Arko Petroleum Corp. (APC.US) submitted IPO applications in December last year.

According to the prospectus, Aktis was founded in 2021 and is committed to developing technology for treating solid tumors using alpha particle radiation targeted therapy. In the nine months ended September 30 last year, the company had revenue of US$4.6 million and a net loss of US$48.6 million; compared with revenue of US$554 million and a net loss of US$31.9 million in the same period last year.

Currently, Aktis has raised approximately US$346 million from a consortium of top life science institutions including MPM, Vida, EcoR1 Capital, and Blue Owl Capital.

The prospectus also revealed that prior to the IPO, MPM affiliates held 26% of Aktis's shares, Vida Ventures held 14%, EcoR1 held 11%, and Blue Owl held 7%.

The offering was led by J.P. Morgan Chase, Bank of America, Leerink Partners, and Toronto Dominion Bank. The company plans to list on the NASDAQ Global Market under the ticker AKTS.